Search research articles
Contact Us
Filters
Showing results (1-10 of 8) with videos related to
Page
of 1
Sort By:
Cancer Treatment Reviews
|
September 1, 1985
Results of NCI-sponsored phase I trials with carboplatin
B J Foster, K Clagett-Carr, B Leyland-Jones, et al.
Cancer Treatment Reports
|
November 1, 1986
Gallium nitrate: the second metal with clinical activity
B J Foster, K Clagett-Carr, D Hoth, et al.
Cancer Treatment Reports
|
March 1, 1986
Pentamethylmelamine: review of an aqueous analog of hexamethylmelamine
B J Foster, K Clagett-Carr, D Hoth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 1988
N-methylformamide: cytotoxic, radiosensitizer, or chemosensitizer
K Clagett-Carr, G Sarosy, J Plowman, et al.
Cancer Treatment Reports
|
August 1, 1986
Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?
B J Foster, K Clagett-Carr, S Marsoni, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1990
A strategy for the development of two clinically active cisplatin analogs: CBDCA and CHIP
B J Foster, B J Harding, M K Wolpert-DeFilippes, et al.
Investigational New Drugs
|
January 1, 1985
Echinomycin: the first bifunctional intercalating agent in clinical trials
B J Foster, K Clagett-Carr, D D Shoemaker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 1992
Patient treatment on a compassionate basis: documentation of high adverse drug reaction rate
B Leyland-Jones, B R Davies, K Clagett-Carr, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 8) with videos related to
Sort By:
Page
of 1
Cancer Treatment Reviews
|
September 1, 1985
Results of NCI-sponsored phase I trials with carboplatin
B J Foster, K Clagett-Carr, B Leyland-Jones, et al.
Cancer Treatment Reports
|
November 1, 1986
Gallium nitrate: the second metal with clinical activity
B J Foster, K Clagett-Carr, D Hoth, et al.
Cancer Treatment Reports
|
March 1, 1986
Pentamethylmelamine: review of an aqueous analog of hexamethylmelamine
B J Foster, K Clagett-Carr, D Hoth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 1988
N-methylformamide: cytotoxic, radiosensitizer, or chemosensitizer
K Clagett-Carr, G Sarosy, J Plowman, et al.
Cancer Treatment Reports
|
August 1, 1986
Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?
B J Foster, K Clagett-Carr, S Marsoni, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1990
A strategy for the development of two clinically active cisplatin analogs: CBDCA and CHIP
B J Foster, B J Harding, M K Wolpert-DeFilippes, et al.
Investigational New Drugs
|
January 1, 1985
Echinomycin: the first bifunctional intercalating agent in clinical trials
B J Foster, K Clagett-Carr, D D Shoemaker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 1992
Patient treatment on a compassionate basis: documentation of high adverse drug reaction rate
B Leyland-Jones, B R Davies, K Clagett-Carr, et al.
Page
of 1